Effect of Ezetimibe on the Prevention and Dissolution of Cholesterol Gallstones

Helen H. Wang, Piero Portincasa, Nahum Mendez-Sanchez, Misael Uribe, David Q.H. Wang

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Background & Aims: Cholesterol cholelithiasis is one of the most prevalent and most costly digestive diseases in developed countries and its incidence has increased markedly in Asian countries owing to the adoption of Western-type dietary habits. Because animal experiments showed that high efficiency of intestinal cholesterol absorption contributes to gallstone formation, we explored whether the potent cholesterol absorption inhibitor ezetimibe could prevent gallstones and promote gallstone dissolution in mice and reduce biliary cholesterol content in human beings. Methods: Male gallstone-susceptible C57L mice were fed a lithogenic diet and concomitantly administered with ezetimibe at 0, 0.8, 4, or 8 mg/kg/day for 8 or 12 weeks. Gallbladder biles and gallstones were examined by microscopy. Gallbladder emptying in response to cholecystokinin octapeptide was measured gravimetrically. Biliary lipid outputs were analyzed by physical-chemical methods. Cholesterol absorption efficiency was determined by fecal dual-isotope ratio and mass balance methods. Lipid changes in gallbladder biles of gallstone patients vs overweight subjects without gallstones were examined before (day 0) and at 30 days after ezetimibe treatment (20 mg/day). Results: Ezetimibe prevented gallstones by effectively reducing intestinal cholesterol absorption and biliary cholesterol secretion, and protected gallbladder motility function by desaturating bile in mice. Treatment with ezetimibe promoted the dissolution of gallstones by forming an abundance of unsaturated micelles. Furthermore, ezetimibe significantly reduced biliary cholesterol saturation and retarded cholesterol crystallization in biles of patients with gallstones. Conclusions: Ezetimibe is a novel approach to reduce biliary cholesterol content and a promising strategy for preventing or treating cholesterol gallstones by inhibiting intestinal cholesterol absorption.

Original languageEnglish (US)
Pages (from-to)2101-2110
Number of pages10
JournalGastroenterology
Volume134
Issue number7
DOIs
StatePublished - Jun 1 2008
Externally publishedYes

Fingerprint

Gallstones
Cholesterol
Bile
Intestinal Absorption
Gallbladder
Ezetimibe
Gallbladder Emptying
Anticholesteremic Agents
Lipids
Sincalide
Cholelithiasis
Micelles
Feeding Behavior
Crystallization
Developed Countries
Isotopes
Microscopy
Diet

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Effect of Ezetimibe on the Prevention and Dissolution of Cholesterol Gallstones. / Wang, Helen H.; Portincasa, Piero; Mendez-Sanchez, Nahum; Uribe, Misael; Wang, David Q.H.

In: Gastroenterology, Vol. 134, No. 7, 01.06.2008, p. 2101-2110.

Research output: Contribution to journalArticle

Wang, Helen H. ; Portincasa, Piero ; Mendez-Sanchez, Nahum ; Uribe, Misael ; Wang, David Q.H. / Effect of Ezetimibe on the Prevention and Dissolution of Cholesterol Gallstones. In: Gastroenterology. 2008 ; Vol. 134, No. 7. pp. 2101-2110.
@article{5eb249d8ceb045e49c1b25fb45b6daf9,
title = "Effect of Ezetimibe on the Prevention and Dissolution of Cholesterol Gallstones",
abstract = "Background & Aims: Cholesterol cholelithiasis is one of the most prevalent and most costly digestive diseases in developed countries and its incidence has increased markedly in Asian countries owing to the adoption of Western-type dietary habits. Because animal experiments showed that high efficiency of intestinal cholesterol absorption contributes to gallstone formation, we explored whether the potent cholesterol absorption inhibitor ezetimibe could prevent gallstones and promote gallstone dissolution in mice and reduce biliary cholesterol content in human beings. Methods: Male gallstone-susceptible C57L mice were fed a lithogenic diet and concomitantly administered with ezetimibe at 0, 0.8, 4, or 8 mg/kg/day for 8 or 12 weeks. Gallbladder biles and gallstones were examined by microscopy. Gallbladder emptying in response to cholecystokinin octapeptide was measured gravimetrically. Biliary lipid outputs were analyzed by physical-chemical methods. Cholesterol absorption efficiency was determined by fecal dual-isotope ratio and mass balance methods. Lipid changes in gallbladder biles of gallstone patients vs overweight subjects without gallstones were examined before (day 0) and at 30 days after ezetimibe treatment (20 mg/day). Results: Ezetimibe prevented gallstones by effectively reducing intestinal cholesterol absorption and biliary cholesterol secretion, and protected gallbladder motility function by desaturating bile in mice. Treatment with ezetimibe promoted the dissolution of gallstones by forming an abundance of unsaturated micelles. Furthermore, ezetimibe significantly reduced biliary cholesterol saturation and retarded cholesterol crystallization in biles of patients with gallstones. Conclusions: Ezetimibe is a novel approach to reduce biliary cholesterol content and a promising strategy for preventing or treating cholesterol gallstones by inhibiting intestinal cholesterol absorption.",
author = "Wang, {Helen H.} and Piero Portincasa and Nahum Mendez-Sanchez and Misael Uribe and Wang, {David Q.H.}",
year = "2008",
month = "6",
day = "1",
doi = "10.1053/j.gastro.2008.03.011",
language = "English (US)",
volume = "134",
pages = "2101--2110",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Effect of Ezetimibe on the Prevention and Dissolution of Cholesterol Gallstones

AU - Wang, Helen H.

AU - Portincasa, Piero

AU - Mendez-Sanchez, Nahum

AU - Uribe, Misael

AU - Wang, David Q.H.

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Background & Aims: Cholesterol cholelithiasis is one of the most prevalent and most costly digestive diseases in developed countries and its incidence has increased markedly in Asian countries owing to the adoption of Western-type dietary habits. Because animal experiments showed that high efficiency of intestinal cholesterol absorption contributes to gallstone formation, we explored whether the potent cholesterol absorption inhibitor ezetimibe could prevent gallstones and promote gallstone dissolution in mice and reduce biliary cholesterol content in human beings. Methods: Male gallstone-susceptible C57L mice were fed a lithogenic diet and concomitantly administered with ezetimibe at 0, 0.8, 4, or 8 mg/kg/day for 8 or 12 weeks. Gallbladder biles and gallstones were examined by microscopy. Gallbladder emptying in response to cholecystokinin octapeptide was measured gravimetrically. Biliary lipid outputs were analyzed by physical-chemical methods. Cholesterol absorption efficiency was determined by fecal dual-isotope ratio and mass balance methods. Lipid changes in gallbladder biles of gallstone patients vs overweight subjects without gallstones were examined before (day 0) and at 30 days after ezetimibe treatment (20 mg/day). Results: Ezetimibe prevented gallstones by effectively reducing intestinal cholesterol absorption and biliary cholesterol secretion, and protected gallbladder motility function by desaturating bile in mice. Treatment with ezetimibe promoted the dissolution of gallstones by forming an abundance of unsaturated micelles. Furthermore, ezetimibe significantly reduced biliary cholesterol saturation and retarded cholesterol crystallization in biles of patients with gallstones. Conclusions: Ezetimibe is a novel approach to reduce biliary cholesterol content and a promising strategy for preventing or treating cholesterol gallstones by inhibiting intestinal cholesterol absorption.

AB - Background & Aims: Cholesterol cholelithiasis is one of the most prevalent and most costly digestive diseases in developed countries and its incidence has increased markedly in Asian countries owing to the adoption of Western-type dietary habits. Because animal experiments showed that high efficiency of intestinal cholesterol absorption contributes to gallstone formation, we explored whether the potent cholesterol absorption inhibitor ezetimibe could prevent gallstones and promote gallstone dissolution in mice and reduce biliary cholesterol content in human beings. Methods: Male gallstone-susceptible C57L mice were fed a lithogenic diet and concomitantly administered with ezetimibe at 0, 0.8, 4, or 8 mg/kg/day for 8 or 12 weeks. Gallbladder biles and gallstones were examined by microscopy. Gallbladder emptying in response to cholecystokinin octapeptide was measured gravimetrically. Biliary lipid outputs were analyzed by physical-chemical methods. Cholesterol absorption efficiency was determined by fecal dual-isotope ratio and mass balance methods. Lipid changes in gallbladder biles of gallstone patients vs overweight subjects without gallstones were examined before (day 0) and at 30 days after ezetimibe treatment (20 mg/day). Results: Ezetimibe prevented gallstones by effectively reducing intestinal cholesterol absorption and biliary cholesterol secretion, and protected gallbladder motility function by desaturating bile in mice. Treatment with ezetimibe promoted the dissolution of gallstones by forming an abundance of unsaturated micelles. Furthermore, ezetimibe significantly reduced biliary cholesterol saturation and retarded cholesterol crystallization in biles of patients with gallstones. Conclusions: Ezetimibe is a novel approach to reduce biliary cholesterol content and a promising strategy for preventing or treating cholesterol gallstones by inhibiting intestinal cholesterol absorption.

UR - http://www.scopus.com/inward/record.url?scp=44849142781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44849142781&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2008.03.011

DO - 10.1053/j.gastro.2008.03.011

M3 - Article

C2 - 18442485

AN - SCOPUS:44849142781

VL - 134

SP - 2101

EP - 2110

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 7

ER -